Improving Subject Selection And Endpoint Management In Alzheimer's Trials

The rapidly growing burden of Alzheimer’s disease worldwide, and the high attrition rate in trials of disease- modifying drugs for AD, call for better-designed clinical research, particularly in terms of selecting the right patients and making sure that endpoints are clear, transparent and well-supported.

WCG has years of expertise in helping AD trial sponsors to design effective protocols, identify and recruits the most appropriate participants, and collect consistent, accurate, reliable endpoints. Our Virgil electronic data-capture platform ensures that trial inputs and outcomes product definitive positive or negative data to inform next steps in drug development/